Feb. 10 at 11:50 PM
$CPHI AI Overview
Hainan Helpson Medical & Biotechnology, a subsidiary of China Pharma Holdings, agreed to acquire an invention patent for a Topiroxostat nanoemulsion and its preparation method from inventor Xiaoyun Chen for
$8.82 million. The deal, finalized on February 5, 2026, is settled via issuing 12,600,000 restricted common shares at
$0.70 each.
Key details of the acquisition include:
Asset Acquired: Full ownership of an invention patent covering a Topiroxostat nanoemulsion and its preparation method.
Total Consideration:
$8.82 million.
Payment Method: 12,600,000 restricted shares of China Pharma common stock at
$0.70 per share.
Significance: This acquisition is expected to strengthen Hainan Helpson's product pipeline in the pharmaceutical market.
